Potential effect of proton-pump inhibitor on angiogenic markers in preeclampsia
Recruiting
- Conditions
- Preeclampsia
- Registration Number
- NL-OMON22488
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 44
Inclusion Criteria
Women (=18 years) with a singleton pregnancy diagnosed with PE with a gestational age of = 20 weeks and <35 weeks admitted to the obstetric department who give written informed consent, will be included.
Exclusion Criteria
- Multiple pregnancies
- Not willing to give written informed consent.
- Other reasons than (suspected) PE requiring hospitalization
- The use of PPI at time of randomization
- Contraindications or hypersensitivity to PPI use
- The use of medication affected by PPI
- Fetal death at time of inclusion
- Signs of fetal distress at time of inclusion
- Expected delivery of = 2 days
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The difference in sFlt-1 levels in women who have received PPI, in comparison to women who have not received PPI.
- Secondary Outcome Measures
Name Time Method The difference in other biomarkers such as PlGF, ET-1, sEndoglin, CT-proET-1 in women who have received PPI, in comparison to women who have not received PPI